Patent 12011427 was granted and assigned to Inspirna, Inc. on June, 2024 by the United States Patent and Trademark Office.
The invention features methods of treating cancer with β-GPA. The disclosure also provides methods of treating cancer including combinations of β-GPA and additional anti-cancer therapies.